Samy M El-Megharbel
The chromium (III) metformin hydrochloride complex as a diabetic drug model was synthesised by the chemical reaction between chromium (III) chloride hexahydrateand metforminHCl (Mfn.HCl) in methanol solvent. The [Cr(Mfn-HCl)2(Cl)2].Cl.6H2O complex was characterized using microanalytical measurements, molar conductance, spectroscopic (infrared, and UV-vis.), effective magnetic moment, and thermal analyses. The infrared spectroscopic data in the comparison between free Mfn.HCl ligand and its chromium (III) complex proved that metformin hydrochloride react with chromium(III) ions as a bidentate ligand through its two imino groups. The anti-diabetic activities of the Mfn.HCl drug, chromium salt and Cr (III)-2Mfn.HCl complex were discussed on the male rats. The chromium (III) metformin HCl complex was recorded successful efficiency in the decreasing blood glucose level and HbA1C against diabetic rats. The Cr(III)-2Mfn.HCl complex has succeeded to great extent as antidaibetic drug with enhanced the antioxidant defence system as well as act as pronounced efficient hypoglycaemic agent compared to metformin HCl free drug.